Patterns of metastases of prostatic ductal adenocarcinoma

Background The current study was conducted to investigate the patterns of metastases in men with metastatic prostatic ductal adenocarcinoma (DAC) and recurrence patterns after therapy. Methods All patients with a new diagnosis of DAC with de novo metastases and those with localized disease who devel...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2020-08, Vol.126 (16), p.3667-3673
Main Authors: Ranasinghe, Weranja K. B., Brooks, Nathan A., Elsheshtawi, Mohamed A., Davis, John W., Bathala, Tharakeswara K., Tang, Chad, Troncoso, Patricia, Aparicio, Ana, Tu, Shi‐Ming, Pisters, Louis L., Chapin, Brian F.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - diagnosis
Adenocarcinoma - diagnostic imaging
Adenocarcinoma - pathology
Aged
Antigens
Carcinoma, Ductal - diagnosis
Carcinoma, Ductal - diagnostic imaging
Carcinoma, Ductal - pathology
de novo
ductal
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - secondary
Lungs
Male
Medical imaging
Medical treatment
Metastases
Metastasis
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Recurrence, Local - pathology
Oncology
Palliation
Prostate
Prostate - diagnostic imaging
Prostate - pathology
Prostate - surgery
Prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Signs and symptoms
Thorax - diagnostic imaging
Thorax - pathology
Tumors
Viscera
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The current study was conducted to investigate the patterns of metastases in men with metastatic prostatic ductal adenocarcinoma (DAC) and recurrence patterns after therapy. Methods All patients with a new diagnosis of DAC with de novo metastases and those with localized disease who developed metastases after treatment and were treated at the study institution from January 2005 to November 2018 were included. All patient and tumor characteristics and outcome data were collected. Results A total of 164 patients (37.7%) had metastatic DAC, including 112 with de novo metastases and 52 who developed metastases after treatment. Men with de novo metastases were found to have a significantly higher median prostate‐specific antigen level and International Society of Urological Pathology grade but a lower cT3 and/or T4 classification compared with those with metastases that developed after treatment (all P 
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.32957